The ratio of SPARC to vimentin expression was significantly greater in patients with stage III CRC, who had not received adjuvant therapy (p = 0.01), while in patients with stage II CRC, FOXP3+ cell density was significantly greater in those patients who had received adjuvant therapy compared to those who had not (p = 0.04). The gene discussed is FOXP3; the disease is colorectal carcinoma.